"Our baseline results are in line with earlier studies, which have shown an association between glycemic control and urinary 11-DHTXB₂ excretion. In addition, improving glycemic control has been shown to lead to a decreased 11-DHTXB₂ excretion."

"In the present study, the difference in urinary 11-DHTXB₂ excretion was also influenced by C-reactive protein levels, which were different between the study groups and may reflect the influence of the inflammatory state found in diabetes on thromboxane formation."

"Residual TX production, as revealed by different methods, may derive from COX-1 or COX-2.”

"Extra-platelet sources may contribute to aspirin-insensitive TX generation: monocytes/macrophages and vascular endothelial cells express COX-2 in response to inflammatory stimuli, and the up regulation of COX-2 activity may account for a TX biosynthesis not sensitive to once daily low-dose aspirin."

“Studies consistently report that groups of individuals with major depressive disorder (MDD) demonstrate increased levels of a variety of peripheral inflammatory biomarkers when compared with groups of nondepressed individuals."

 “Two randomized, placebo-controlled studies have reported that the addition of an inhibitor of the cyclooxygenase enzyme to a standard antidepressant enhances symptomatic improvement in medically healthy individuals with depression.  Similarly, preclinical and clinical data suggest that acetylsalicylic acid (aspirin) may hold promise as an augmenting strategy in patients who fail to respond to monotherapy with a serotonin reuptake inhibitor."

"Diabetic patients commonly present an increased risk for cardiovascular events, for which aspirin is the most frequently used medication for primary prevention.  Urinary 11-dehydro thromboxane (11-dhTXB₂) concentrations assess the effect of aspirin on platelets and identify patients who are at risk of cardiovascular events.  The present study investigated whether or not type 2 diabetic patients who took a daily dose of 100 mg of aspirin had a signficant reduction in urinary 11-dhTXB₂ concentrations and whether these results were associated with clinical and laboratory variables."

“Most patients enrolled in the present study also presented a reduced or minimal response to low-dose aspirin therapy, thereby indicating a clear variability related to aspirin effectiveness."

"Incomplete inhibition of platelet thromboxane generation, as measured by elevated urinary 11-dehydrothromboxane B₂ concentrations, has been associated with an increased risk of cardiovascular events.  We aimed to determine the external validity of this association in aspirin-treated patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial and to determine whether thare are any modifiable factors or interventions that lower urinary 11-dehydro thromboxane B₂ concentrations that could thereby reduce cardiovascular risk."

"In aspirin-treated patients, urinary concentrations of 11-dehydrothromboxane B₂ are an externally valid and potentially modifiable determinant of stroke, myocardial infarction, or cardiovascular death in patients at risk for atherothrombotic events."

"Incomplete inhibition of platelet thromboxane generation, as measured by elevated urinary 11-dehydrothromboxane B₂ concentrations, has been associated with an increased risk of cardiovascular events.  We aimed to determine the external validity of this association in aspirin-treated patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial and to determine whether there are any modifiable factors or interventions that lower urinary 11-dehydro thromboxane B₂ concentrations that could thereby reduce cardiovascular risk."

"In aspirin-treated patients, urinary concentrations of 11-dehydrothromboxane B₂ are an externally valid and potentially modifiable determinant of stroke, myocardial infarction or cardiovascular death in patients at risk for atherothrombotic events."

"The antiplatelet effect of aspirin is attributed to platelet cyclooxygenase-1 inhibition.  Controversy exists on the prevalence of platelet resistance to aspirin in patients with coronary artery disease and effects of aspirin dose on inhibition.  Our primary aim was to determine the degree of platelet aspirin responsiveness in patients, as measured by commonly used methods, and to study the relation of aspirin dose to platelet inhibition."

"Meta-analyses of clinical trials have indicated that aspirin treatment of patients with vascular disease is associated with a 25% to 44% reduction in adverse cardiovascular events.  The antithrombotic effect of aspirin has been primarily attributed to the irreversible blockade of the cyclooxygenase-1 (COX-1) enzyme in platelets that leads to attenuation in the production of an important platelet agonist, thromboxane A_2.  In recent years, an increasing number of reports about aspirin resistance has led to a growing concern among clinicians and patients about the efficacy of aspirin treatment.  Various studies have evaluated the antiplatelet effect of aspirin therapy and have reported the prevalence of aspirin resistance to be between 9.4% to 35%."

"The primary established effect of aspirin on hemostasis is to impair platelet aggregation via inhibition of platelet thromboxane A₂ synthesis, thus reducing thrombus formation on the surface of the damaged arterial wall."

We review a number of the reported effects of aspirin on 3 basic elements of hemostasis: platelet activation and aggregation, the formation of the fibrin network, and the fibrinolytic process.

Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients.  Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients."

“Diabetic patients with CAD treated with 81 mg aspirin exhibit a higher prevalence of aspirin resistance and have significantly higher ADP- and collagen-induced platelet aggregation, 11-DHXTB₂ levels, and aspirin reaction units measured by Verify Now than nondiabetic patients.”

"Epidemiological evidence indicates that inflammation accompanies the progression of atherosclerosis.  The aim of the present cross-sectional study was to define relationships between platelet activation and inflammation in patients with mild to severe (stages II to IV) peripheral arterial occlusive disease (PAOD) and matched controls.  The effect of chronic administration of low-dose acetylsalicylic acid was investigated."

“A positive correlation between 11-DHTXB₂ and CRP was found in the study population.”